2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.74 (Poster) LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

PP01.74 (Poster) LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

Back to course

Pdf Summary

A prospective multicenter study sponsored by Lucence Health Inc. compared the performance of two liquid biopsy tests, LiquidHALLMARK and Guardant360, in detecting guideline-recommended biomarkers in patients with metastatic non-squamous non-small cell lung cancer (NSCLC). Tissue genotyping is the standard method for biomarker testing, but it fails in a significant percentage of patients due to insufficient or unavailable tissue for biopsy. The study aimed to evaluate the clinical utility of ctRNA analysis by LiquidHALLMARK for detecting oncogenic gene fusions, exon skipping variants, and transcript variants. <br /><br />The primary analysis included 151 patients enrolled in the study, and it demonstrated that liquid biopsy is useful for identifying guideline-recommended biomarkers in metastatic non-squamous NSCLC. LiquidHALLMARK ctDNA testing detected more tissue-confirmed guideline-recommended biomarkers in lung cancer than Guardant360. This is the first prospective evidence that combining ctDNA and ctRNA for liquid biopsy testing in lung cancer provides additional clinical utility over ctDNA alone. <br /><br />In a subset analysis of patients with tissue-confirmed biomarkers, LiquidHALLMARK-ctDNA demonstrated a concordance of 92.6-100% with Guardant360. LiquidHALLMARK-ctDNA detected 52 out of 68 G9 biomarkers, while Guardant360 detected 45. The concordance between LiquidHALLMARK and tissue genotyping was also high, at 93.2-100%. <br /><br />The study findings suggest that LiquidHALLMARK, an amplicon-based next-generation sequencing liquid biopsy assay, can be a valuable tool for detecting actionable biomarkers in plasma. The inclusion of ctRNA analysis increases the detection of oncogenic gene fusions and other variants, providing further clinical utility. Overall, liquid biopsy testing with LiquidHALLMARK shows promise as a non-invasive alternative to tissue genotyping for personalized treatment selection in NSCLC patients.

Asset Subtitle

Jens Samol

Keywords

multicenter study

liquid biopsy tests

LiquidHALLMARK

Guardant360

metastatic non-squamous non-small cell lung cancer

biomarker testing

ctRNA analysis

oncogenic gene fusions

exon skipping variants

transcript variants